代偿期肝硬化丙型肝炎病毒治疗后骨骼肌质量的改善。

Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Japan.

Department of Medical Innovation, Osaka University Hospital, Japan.

Intern Med. 2021;60(5):745-750. doi: 10.2169/internalmedicine.6029-20. Epub 2021 Mar 1.

Hepatitis C virus (HCV) can be eliminated by direct-acting antivirals in patients with decompensated liver cirrhosis. Although viral clearance in decompensated liver cirrhosis leads to improvement of the liver function and quality of life, changes in the skeletal muscle mass after sustained virologic response (SVR) in patients with decompensated liver cirrhosis have not been reported. We present the first report of skeletal muscle mass improvement with the achievement of SVR for HCV in a 76-year-old woman with decompensated liver cirrhosis. After achieving SVR through ledipasvir/sofosbuvir treatment, the patient showed an improvement in her liver function and an increase in her skeletal muscle mass.

丙型肝炎病毒（HCV）可被直接作用抗病毒药物在失代偿性肝硬化患者中清除。尽管在失代偿性肝硬化中病毒清除可导致肝功能和生活质量的改善，但在失代偿性肝硬化患者中持续病毒学应答（SVR）后骨骼肌质量的变化尚未报道。我们报告了首例通过 Ledipasvir/索磷布韦治疗实现 HCV SVR 后，失代偿性肝硬化患者骨骼肌质量改善的病例。在获得 SVR 后，患者的肝功能改善，骨骼肌质量增加。